Literature DB >> 30035545

Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

Ewgenij Proschak1, Holger Stark2, Daniel Merk1,3.   

Abstract

Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30035545     DOI: 10.1021/acs.jmedchem.8b00760

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  89 in total

1.  Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Lena Hefke; Kerstin Hiesinger; W Felix Zhu; Jan S Kramer; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

2.  Validation strategies for target prediction methods.

Authors:  Neann Mathai; Ya Chen; Johannes Kirchmair
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

3.  Binding site characterization - similarity, promiscuity, and druggability.

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

4.  Harnessing Polypharmacology with Medicinal Chemistry.

Authors:  Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

5.  A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Authors:  Md Abdul Hye Khan; Jurema Schmidt; Anna Stavniichuk; John D Imig; Daniel Merk
Journal:  Biochem Pharmacol       Date:  2019-05-23       Impact factor: 5.858

6.  Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.

Authors:  Filip Miljković; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-12-02       Impact factor: 3.686

7.  A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.

Authors:  Suman Rao; Guangyan Du; Marc Hafner; Kartik Subramanian; Peter K Sorger; Nathanael S Gray
Journal:  J Biol Chem       Date:  2019-03-11       Impact factor: 5.157

8.  Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Kerstin Hiesinger; Annika Schott; Jan S Kramer; René Blöcher; Finja Witt; Sandra K Wittmann; Dieter Steinhilber; Denys Pogoryelov; Jana Gerstmeier; Oliver Werz; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2019-10-30       Impact factor: 4.345

Review 9.  Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors.

Authors:  Hongguang Ma; Boshi Huang; Yan Zhang
Journal:  Drug Discov Today       Date:  2020-07-09       Impact factor: 7.851

10.  Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.

Authors:  Ashish Thakur; Gregory J Tawa; Mark J Henderson; Carina Danchik; Suiyang Liu; Pranav Shah; Amy Q Wang; Garrett Dunn; Md Kabir; Elias C Padilha; Xin Xu; Anton Simeonov; Surender Kharbanda; Richard Stone; Gurmit Grewal
Journal:  J Med Chem       Date:  2020-04-08       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.